Asia-Pacific Biguanide Market – Segmented by Drugs, and Geography – Growth, Trends, and Forecast (2020 - 2025)

Looking to buy the report?

The countries in Asia-Pacific region have high prevalence for diabetes. China and India accounts for close to 83% of diabetic population. The diabetic population in China is expected to cross 150 million by 2045. The type 2 population in most of the countries in the Asia-Pacific region account for about 90% of the diabetic population. Unhealthy diets and sedentary lifestyle are driving increasing rates of overweight and obesity in China which are themselves risk factors for developing Type 2 diabetes. More than one-third of adults in China are overweight, while 7% of adults are obese. As most of the diabetic population in this region are type 2 and as Biguanides are considered to be the first line drugs for type 2 patients, the market for these drugs is huge in the region.


Source: Mordor Intelligence Analysis

In Asia-pacific Biguanide market, China accounts for the close to 71.8% of the market value in 2017. By 2023 the Biguanide market in china will be USD 1169.12 million. Vietnam accounts for the highest CAGR of 3.8% in the Asia-pacific Biguanide market. In developing countries low price of a drug acts as a driver for the market. Metformin is a generic drug in the Biguanide class, thus the cost of these drugs are low. This coupled with the fact that it is the first line of drug treatment for type 2 diabetic patients is the main reason for the high sales of the drug in the Asia-Pacific region.  The Asia-Pacific Biguanide market is USD 9394.13 million in 2017 and is expected to reach USD 10725.33 million during the forecast period. 

Key Players: Mylan, Teva, Takeda, Ranbaxy/Sun Pharma, Dr Reddy’s, Merck, Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals

Key Developments:

June 2018: According to recent scientific studies it is stated that metformin, which has always been a longtime and low-cost drug used to treat diabetes, is safe for most patients who also have chronic kidney disease. This is expected to further boost the sales of the drug.

Dec 2017: Metformin which is a considered to be the first line of drugs for diabetics is now also found safe in pregnant women with diabetics. 

Report Scope:



Base year for estimation


Review Period


Forecast Period

2018 – 2023

Market Representation

Revenue in USD million and CAGR from 2018 – 2023

Regions covered


Report coverage

Revenue forecast and market dynamics

Reasons to Purchase this Report:

  • To study current and future market outlook in the Asia - Pacific Region.
  • Analyzing various perspectives of the market with the help of Porter’s five forces analysis
  • Detailed analysis of the segment that is expected to dominate the market
  • Identifying the latest developments and strategies employed by the major market players
  • 3-month analyst support, along with the Market Estimate sheet in excel

Report Customization and Benefits:

This report can be customized to meet the desired requirements. Please connect with our analyst, who will ensure that you get a report that suits your needs.

1. Introduction

               1.1 Scope of Study

               1.2 Market Definition

               1.3 Executive Summary

2. Research Methodology

               2.1 Study Deliverables

               2.2 Study Assumptions

               2.3 Research Phases

3. Market Insights

               3.1 Technology Trends

               3.2 Industry Attractiveness - Porter's Five Forces Analysis

                              3.2.1 Bargaining Power of the Suppliers

                              3.2.2 Bargaining Power of the Consumers

                              3.2.3 Threat of New Entrants

                              3.2.4 Threat of Substitute Products and Services

                              3.2.5 Competitive Rivalry within the Industry

4.  Market Dynamics

               4.1 Drivers

               4.2 Restraints

               4.3 Opportunities

5. Market Indicators

               5.1 Total Diabetes Population

               5.2 Type 2 Diabetes Population

6. Market Segmentation and Analysis

               6.1 By Drug

                              6.1.1 Metformin

                                    Metformin, Revenue (2012-2023)

                                    Metformin, Volume (2012-2023)

7. Geographical Analysis

               7.1 Asia pacific

                              7.1.1 Australia

                                    Australia, Revenue (2012-2023)

                                    Australia, Volume (2012-2023)

                              7.1.2 India

                                    India, Revenue (2012-2023)

                                    India, Volume (2012-2023)

                              7.1.3 Indonesia

                                    Indonesia, Revenue (2012-2023)

                                    Indonesia, Volume (2012-2023)

                              7.1.4 Thailand

                                    Thailand, Revenue (2012-2023)

                                    Thailand, Volume (2012-2023)

                              7.1.5 Philippines

                                    Philippines, Revenue (2012-2023)

                                    Philippines, Volume (2012-2023)

                              7.1.6 Vietnam

                                    Vietnam, Revenue (2012-2023)

                                    Vietnam, Volume (2012-2023)

                              7.1.7 China

                                    China, Revenue (2012-2023)

                                    China, Volume (2012-2023)

                              7.1.8 South Korea

                                    South Korea, Revenue (2012-2023)

                                    South Korea, Volume (2012-2023)

                              7.1.9 Japan

                                    Japan, Revenue (2012-2023)

                                    Japan, Volume (2012-2023)

                              7.1.10 Malaysia

                                    Malaysia, Revenue (2012-2023)

                                    Malaysia, Volume (2012-2023)

                              7.1.11 Rest of Asia Pacific

                                    Rest of Asia Pacific, Revenue (2012-2023)

                                    Rest of Asia Pacific, Volume (2012-2023)

8. Key Player Profiles

               8.1 Dr Reddy's

               8.2 Lupin

               8.3 Teva

               8.4 Takeda

               8.5 Ranbaxy/Sun Pharma

               8.6 Bayer

               8.7 Mylan

               8.8 Merck

               8.9 Bristol-Myers Squibb

               8.10 Boehringer Ingelheim Pharmaceuticals

* Each Company Profile include overview, Revenue, Product and services, Swot, Recent Activities and strategic Analysis.


Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?



By submitting, you confirm that you agree to our privacy policy